Latest News and Press Releases

Business Reflects Strategic Shift in Legacy Business Model Fort Lauderdale, FL, Aug. 19, 2024 (GLOBE NEWSWIRE) -- The Singing Machine Company, Inc. (“Singing Machine”) (NASDAQ: MICS) – the...

Tulsa, OK, April 17, 2023 (GLOBE NEWSWIRE) -- (OTCQB:GLGI). Tulsa-based Greystone Logistics, Inc. reports results of operations for the nine and three months ended February 28, 2023. ...

‒ Phase 2 EB613 Clinical Trial in Osteoporosis Achieves 3-Month Primary Endpoint; Final Data Including BMD Expected Q2:21 ‒ ‒ Entera’s Oral Delivery Platform Shows Potential in Indications Including...

‒ Achieved Primary Endpoint in EB613 Phase 2 Clinical Trial ‒‒ Final Data, Including Bone Mineral Density, Expected in Q2:21 ‒‒ FDA Approval of EB613 IND for the Treatment of Osteoporosis Enables...

Tulsa, OK, Jan. 19, 2021 (GLOBE NEWSWIRE) -- GREYSTONE LOGISTICS, INC. (OTCQB:GLGI). Tulsa-based Greystone Logistics, Inc. reports results of operations for the three months and six months ended...

‒ Completed Enrollment in Phase 2 Clinical Trial of EB613, Positioned as the First Potential Oral Bone Building Product to Treat Osteoporosis ‒‒ Positive Interim 6-Month Bone Mineral Density (BMD)...

‒ 6-Month Interim Data Indicate EB 613 Has Meaningful and Positive Impact on Lumbar Spine Bone Mineral Density (BMD) in a Dose Dependent Manner –‒ Company Expects to Complete Patient Enrollment in...

‒ Statistically Significant One Month Increases in P1NP Biomarker from First 50% of Patients with Highest Dose of EB613 ‒‒ Company to Follow Patients in the Phase 2 Clinical Trial of EB613 through Six...

‒ Three Month Biomarker Data from Phase 2 Clinical Trial of EB613 Expected in the Second Quarter of 2020 with Additional Data Readouts Expected in 2020 and Early 2021 ‒‒ Financing Completed in...

BOSTON and JERUSALEM, March 16, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report...